Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report.
We report the successful treatment of a patient with recurrent malignant glioma with adoptive cellular immunotherapy. The patient is a young adult with recurrent progressive disease refractory to aggressive multi-modality therapy including repetitive surgical resection, radiation, radiosurgery and chemotherapy. He received multiple courses of local administration of autologous lymphokine-activated killer (LAK) cells in combination with a low dose of interleukin-2 (IL-2) through an Ommaya reservoir-catheter system. The side-effects of this treatment were limited and manageable. The patient achieved a complete remission, as demonstrated by MRI and confirmed by glucose-positron emission tomography (PET) imaging 11 months after initiation of immune therapy. Twenty-six months later, the patient is still in remission with improving performance status. Adoptive cellular immunotherapy utilizing autologous LAK cells with low dose IL-2 appears to be a safe and effective therapy for a subset of patients with primary, recurrent or progressive malignant glioma following conventional therapy.
Huang
Y
Y
Department of Medicine, Sanford R. Nalitt Institute for Cancer and Blood-Related Diseases, Staten Island University Hospital, 256 Mason Avenue, Staten Island, NY 10305, USA.
Hayes
R L
RL
Wertheim
S
S
Arbit
E
E
Scheff
R
R
D000328:Adult; D005910:Glioma / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000633:toxicity; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D008297:Male; D012008:Recurrence; D016879:Salvage Therapy
D007376:Interleukin-2